# Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act - FDA Guidance Document Source: https://www.globalkeysolutions.net/guidances/guidance-document/notifying-fda-of-a-discontinuance-or-interruption-in-manufacturing-of-finished-products-or-active-pharmaceutical-ingredients-under-section-506c-of-the-fdc-act/4bb3edae-dd26-480a-a41b-2f2b6bd19311 > FDA guidance document: Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act. Issue date: February 06, 2024. Get complete insights and analysis. --- ## Details - Title: Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act - Communication Type: Guidance Document - Product Type: drugs - Office Name: Center for Drug Evaluation and Research - Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c - Issue Date: 2024-02-06 - Comment Close Date: 2023-06-05 - Last Changed: 2024-02-05 - Docket Number: FDA-2020-D-1057 ## Related Documents - [Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers](https://www.globalkeysolutions.net/guidances/guidance-document/postapproval-manufacturing-changes-to-biosimilar-and-interchangeable-biosimilar-products-questions-and-answers/f791f37f-3382-48a9-8fcb-f27046ac94a4) - [Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products](https://www.globalkeysolutions.net/guidances/guidance-document/real-world-evidence-considerations-regarding-non-interventional-studies-for-drug-and-biological-products/48325e39-b445-4a53-8cc0-7483dcf3e352) - [Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff](https://www.globalkeysolutions.net/guidances/guidance-document/biomarker-qualification-evidentiary-framework-draft-guidance-for-industry-and-fda-staff/c198796d-4230-4499-a6ee-2f84eed424c9)